IgA肾病采用活性维生素D联合血管紧张素受体拮抗剂治疗的临床价值探析

An Investigation into Clinical Value of Activated Vitamin D Plus ARB on IgAN

目的:对活性维生素D(VD3)联合血管紧张素受体拮抗剂(ARB)治疗IgA肾病患者的临床价值进行探讨。方法:选取63例IgA肾病患者作为研究对象,运用随机双盲法对其分组,主要分为研究组(32例)和对照组(31例),对照组患者单独给予VD3治疗,研究组患者在对照组患者治疗基础上联合ARB治疗。结果:研究组患者的舒张压、收缩压、血磷、血钙以及Cr等指标与治疗前对比(P>0.05);研究组患者的尿蛋白水平显著低于对照组(P<0.05)。结论:治疗IgA肾病患者应用VD3联合ARB疗法,具有较高的安全性,能够大大降低患者的尿蛋白指标,可在临床范围内广泛推广应用。

Objective:To investigate the clinical value of activated vitamin D Plus ARB to the treatment of IgAN.Methods:Select 64 patients with IgAN as the research object and group them in accordance with random double-blind method,namely research group(n=32)and control group(n=31),the control group were merely treated with VD3,and while the research group were added with ARB based on the treatment in research group.Results:To compare diastolic pressure,systolic pressure,serum inorganic phosphorus,serum calcium,Cr and other indicators of the patients in research group with that before,P>0.05;the proteinuria level of the patients in research group was obviously lower than that in control group(P<0.05).Conclusion:It is safe to treat patients with IgAN with VD3 plus ARB and it would significantly lower the level of proteinuria,it is worthy of clinical promotion and application.